A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
A Stability Indicating HPTLC Method Development and Validation for Analysis of Sitagliptin As Bulk Drug And In Formulation
2019
American Journal of PharmTech Research
Sitagliptin chemically is (3R) -3-amino-1- [3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4] triazolo [3,4-c] pyrazin-7-yl]-4-(2,4,5-trifluorophenyl) butan-1-one ( Fig. 1) , an oral anti-diabetic agent that blocks Dipeptidyl peptidase-4 (DPP-4) activity. Sitagliptin increased incretin levels (GLP-1 and GIP) which inhibit glucagon release, in turn decreases blood glucose, but more significantly increases insulin secretion. The present work describes development and validation of a new simple,
doi:10.46624/ajptr.2019.v9.i6.009
fatcat:ngxc4dhmpndernag2rndh6fxju